CGON is a biotech play with a Phase 3 bladder cancer drug (cretostimogene grenadenorepvec) facing a key PIVOT-006 data readout in 1H 2026; the post suggests a short squeeze setup with crowded shorts and binary catalyst potential, though biotech trials carry execution risk and failure could result in significant losses.